Visit the Aggrego Advances hub to learn more about various clinical trials. 

Friday
December
02
Top Stories
Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer

Recently, the FDA approved lutetium (177Lu) vipivotide tetraxetan (177Lu-PSMA-617) for the treatment of adult patients with PSMA-positive mCRPC who have been treated with othe

Oncology Times
1w ago
Single Cell Characterization of Myeloma and its Precursor Conditions Reveals Transcriptional Signatures of Early Tumorigenesis

The findings characterize transcriptomic alterations present at the earliest stages of myeloma, providing insight into the molecular underpinnings of disease initiation.

Nature Communications
1w ago
Effect of Baseline Immunosuppression on COVID-19 Severity and Risk of Cytokine Storm in Patients Receiving Immunotherapy for Cancer

In a registry-based retrospective cohort study reported in JAMA Oncology, Ziad Bakouny, MD, and colleagues in the COVID-19 and Cancer Consortium found that patients receiving cancer immuno

The ASCO Post
1w ago
Deep Learning for the Detection of Anatomical Tissue Structures and Neoplasms of the Skin on Scanned Histopathological Tissue Sections

The study authors show that the automated identification and classification of common skin tumors is possible by deep learning on scanned histological tissue sections and may contribute to an effic

Frontiers in Oncology
1w ago

Spotlight

The Clinical study of REsponse to Seribantumab in TumOrs with NEuregulin 1 (NRG1) fusions, or CRESTONE, is a single arm phase 2 study exploring the anti-tumor activity and tolerability of seribantumab in patients with advanced solid tumors and an NRG1 gene fusion. 

Radio
Lung Cancer
Aggrego Oncology - 3/24/22
Aggrego Oncology
8m ago
Aggrego Pulse - 10/07/21
Aggrego Oncology
1y ago